AMNEAL PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $930.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2025-02-28
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-09-30 was $1.03M.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was -$100.00K.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $930.00K, a 93.58% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $14.50M.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$731.00K.
- AMNEAL PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was -$200.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.03M derived: sum of 2 quarters · filed 2025-02-28 | $1.03M derived: sum of 3 quarters · filed 2025-02-28 | $930.00K 10-K · filed 2025-02-28 |
| 2024-09-30 | $1.03M 10-Q · filed 2024-11-12 | $1.03M derived: sum of 2 quarters · filed 2024-11-12 | $930.00K 10-Q · filed 2024-11-12 | $14.64M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | -$100.00K 10-Q · filed 2024-08-09 | $13.61M derived: sum of 3 quarters · filed 2025-02-28 | $10.49M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | -$100.00K 10-Q · filed 2024-05-08 | $13.61M derived: sum of 2 quarters · filed 2025-02-28 | $10.49M derived: sum of 3 quarters · filed 2025-02-28 | $16.85M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | $13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $10.59M derived: sum of 2 quarters · filed 2025-02-28 | $16.95M derived: sum of 3 quarters · filed 2025-02-28 | $14.50M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$3.12M 10-Q · filed 2024-11-12 | $3.24M derived: sum of 2 quarters · filed 2024-11-12 | $787.00K 10-Q · filed 2024-11-12 | -$1.44M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $6.36M 10-Q · filed 2024-08-09 | $3.91M 10-Q · filed 2024-08-09 | $1.68M derived: sum of 3 quarters · filed 2025-02-28 | $3.11M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$2.46M 10-Q · filed 2024-05-08 | -$4.68M derived: sum of 2 quarters · filed 2025-02-28 | -$3.26M derived: sum of 3 quarters · filed 2025-02-28 | -$2.99M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$801.00K derived: sum of 2 quarters · filed 2025-02-28 | -$531.00K derived: sum of 3 quarters · filed 2025-02-28 | -$731.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.43M 10-Q · filed 2023-11-09 | $1.70M derived: sum of 2 quarters · filed 2023-11-09 | $1.50M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $270.00K 10-Q · filed 2023-08-08 | $70.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$200.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$200.00K 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |